The company has substantially improved its development of an novel therapy for amyloid heart disease, leveraging the investigational drug. Initial patient results reveals potential benefits for patients suffering from https://attr-cm108890.mdkblog.com/48293287/bridgebio-improves-attr-cm-management-with-attruby